# A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

> **NCT00545233** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 155 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin [Copegus]
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00545233
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545233, "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00545233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*